ALLO – allogene therapeutics, inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day ALLO SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
04:05 pm
allo
allogene therapeutics, inc.
BEAT
12.4%
8/13/2025
04:05 pm
allo
allogene therapeutics, inc.
BEAT
0.9%
5/13/2025
04:05 pm
allo
allogene therapeutics, inc.
IN-LINE
-16.4%
5/13/2025
04:05 pm
allo
allogene therapeutics, inc.
IN-LINE
-16.4%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
2/6 Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule 6.8%
3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%
3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%
4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%
4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%
4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%
8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%
3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%
3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%
2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%
Top News Decliners
3/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -15.8%
11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%
8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%
8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%
11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%
4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%
9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%
5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%
11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
ALLO – allogene therapeutics, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
ALLO
SPY
QQQ
SPX
ALLO – allogene therapeutics, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
ALLO SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
11/10
08:30 am
allo
Medium
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
11/7
06:11 pm
allo
Low
Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T [Seeking Alpha]
11/6
04:05 pm
allo
High
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
11/3
09:04 am
allo
Medium
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
10/30
08:30 am
allo
Low
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
10/12
01:08 am
allo
Medium
Allogene Therapeutics (NASDAQ:ALLO) was downgraded by analysts at Wall S
10/10
08:06 am
allo
High
Allogene Therapeutics (NASDAQ:ALLO) had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..
10/4
03:06 am
allo
Medium
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Wall Str
10/2
04:45 am
allo
Low
Clinical Trials Boost CAR T-Cell Therapy as Efficacy Sparks Major Approvals for Non-Hodgkin's Lymphoma [Yahoo! Finance]
11/6/2025
04:05 pm
allo
12.4%
BEAT
8/13/2025
04:05 pm
allo
0.9%
BEAT
5/13/2025
04:05 pm
allo
-16.4%
IN-LINE
5/13/2025
04:05 pm
allo
-16.4%
IN-LINE
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
10/10
08:06 am
Reiterates
Neutral
Underweight
JPMorgan Chase & Co.
High
-15.8%
10/10
07:37 am
Downgrades
Neutral
Underweight
JP Morgan
High
-16.3%
10/10
05:40 am
Downgrades
NEUTRAL
UNDERWEIGHT
JPMORGAN
High
-16.9%
11/19
04:09 pm
allo
Low
Form 4 Allogene Therapeutics, For: Nov 17 Filed by: Beneski Benjamin Machinas
11/17
07:14 pm
allo
Medium
Form 144 Allogene Therapeutics, Filed by: Beneski Benjamin Machinas
11/13
07:10 pm
allo
Medium
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Belldegrun Arie
11/13
07:06 pm
allo
Medium
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Capital World Investors
11/12
04:37 pm
allo
Low
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Chang David D
11/6
04:31 pm
allo
High
Form 10-Q Allogene Therapeutics, For: Sep 30
11/6
04:29 pm
allo
High
Form 8-K Allogene Therapeutics, For: Nov 06
10/23
06:21 pm
allo
Low
Form 4 Allogene Therapeutics, For: Oct 21 Filed by: Parker Geoffrey M.
10/21
08:52 pm
allo
Medium
Form 144 Allogene Therapeutics, Filed by: Parker Geoffrey M.
Show more
Top News Gainers
2/6 Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule 6.8%
3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%
3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%
4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%
4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%
4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%
8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%
3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%
3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%
2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%
Top News Decliners
3/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -15.8%
11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%
8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%
8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%
11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%
4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%
9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%
5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%
11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%